Back to top

Enanta Advances RSV Antiviral Zelicapavir to Registrational Trial

Enanta Pharmaceuticals ( ($ENTA) ) just unveiled an update. On June 18, 2026, Enanta announced it will advance its RSV antiviral candidate zelicapa...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Enanta Pharmaceuticals, Inc. (ENTA)